| Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA AR Thierry, F Mouliere, S El Messaoudi, C Mollevi, E Lopez-Crapez, ... Nature medicine 20 (4), 430-435, 2014 | 748 | 2014 |
| Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab … F Bibeau, E Lopez-Crapez, F Di Fiore, S Thezenas, M Ychou, F Blanchard, ... Journal of clinical oncology 27 (7), 1122-1129, 2009 | 617 | 2009 |
| Circulating DNA as a strong multimarker prognostic tool for metastatic colorectal cancer patient management care S El Messaoudi, F Mouliere, S Du Manoir, C Bascoul-Mollevi, B Gillet, ... Clinical Cancer Research 22 (12), 3067-3077, 2016 | 183 | 2016 |
| Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load F Mouliere, S El Messaoudi, C Gongora, AS Guedj, B Robert, M Del Rio, ... Translational oncology 6 (3), 319-IN8, 2013 | 174 | 2013 |
| Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study B Iacopetta, A Russo, V Bazan, G Dardanoni, N Gebbia, T Soussi, D Kerr, ... Annals of oncology 17 (5), 842-847, 2006 | 162 | 2006 |
| Europium (III) cryptate: a fluorescent label for the detection of DNA hybrids on solid support. MG Prat O, Lopez E Anal Biochem 195 (2), 283-9, 1991 | 139 | 1991 |
| FTO-mediated cytoplasmic m6Am demethylation adjusts stem-like properties in colorectal cancer cell S Relier, J Ripoll, H Guillorit, A Amalric, C Achour, F Boissière, J Vialaret, ... Nature communications 12 (1), 1716, 2021 | 129 | 2021 |
| Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment AR Thierry, S El Messaoudi, C Mollevi, JL Raoul, R Guimbaud, D Pezet, ... Annals of Oncology 28 (9), 2149-2159, 2017 | 114 | 2017 |
| Cetuximab plus FOLFIRINOX (ERBIRINOX) as first‐line treatment for unresectable metastatic colorectal cancer: a phase II trial E Assenat, F Desseigne, S Thezenas, F Viret, L Mineur, A Kramar, ... The oncologist 16 (11), 1557-1564, 2011 | 101 | 2011 |
| Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using … N Gaborit, C Larbouret, J Vallaghe, F Peyrusson, C Bascoul-Mollevi, ... Journal of Biological Chemistry 286 (13), 11337-11345, 2011 | 92 | 2011 |
| K-ras Mutation Detection by Hybridization to a Polypyrrole DNA Chip E Lopez-Crapez, T Livache, J Marchand, J Grenier Clinical chemistry 47 (2), 186-194, 2001 | 83 | 2001 |
| B. Alpha and G. Mathis E Lopez, C Chypre Clin. Chem 39 (2), 196, 1993 | 83 | 1993 |
| KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues J Solassol, J Ramos, E Crapez, M Saifi, A Mangé, E Vianès, PJ Lamy, ... International journal of molecular sciences 12 (5), 3191-3204, 2011 | 70 | 2011 |
| Sorafenib and irinotecan (NEXIRI) as second-or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial E Samalin, O Bouche, S Thézenas, E Francois, A Adenis, J Bennouna, ... British journal of cancer 110 (5), 1148-1154, 2014 | 68 | 2014 |
| Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers S Guiu, C Mollevi, C Charon-Barra, F Boissière, E Crapez, E Chartron, ... British journal of cancer 119 (1), 76-79, 2018 | 66 | 2018 |
| Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY” phase 1-2 … E Assenat, D Azria, C Mollevi, R Guimbaud, N Tubiana-Mathieu, D Smith, ... Oncotarget 6 (14), 12796, 2015 | 66 | 2015 |
| Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization A Ho-Pun-Cheung, C Bascoul-Mollevi, E Assenat, F Boissière-Michot, ... BMC molecular biology 10, 1-10, 2009 | 65 | 2009 |
| BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer W Jacot, S Thezenas, R Senal, C Viglianti, AC Laberenne, ... Bmc Cancer 13, 1-11, 2013 | 63 | 2013 |
| p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis E Lopez-Crapez, F Bibeau, S Thezenas, M Ychou, J Simony-Lafontaine, ... British journal of cancer 92 (12), 2114-2121, 2005 | 59 | 2005 |
| Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer … W Jacot, E Lopez-Crapez, S Thezenas, R Senal, F Fina, F Bibeau, ... Breast Cancer Research 13, 1-9, 2011 | 52 | 2011 |
